z-logo
Premium
Therapeutic progress III: Diabetic nephropathy
Author(s) -
Maxwell S. R. J.,
Gittoes N. J. L.
Publication year - 1994
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.1994.tb00815.x
Subject(s) - medicine , diabetic nephropathy , nephropathy , dialysis , renal function , hypertensive nephropathy , diabetes mellitus , intensive care medicine , urology , endocrinology
SUMMARY Diabetic nephropathy is a common cause of end stage renal failure. Patients ultimately require dialysis or transplantation and endure a poor quality of life in association with increased mortality. Due to the quantitative significance of this problem there is also a considerable financial burden. It has been generally accepted that once nephropathy is established it is irreversible although aggressive anti‐hypertensive treatment can delay its progression. More recently there have been numerous reports proposing a specific renal protective role of certain drugs. In this article we review the current literature on the use of angiotensin converting enzyme inhibitors in diabetic nephropathy. There is strong evidence that the use of ACE inhibitors in diabetic nephropathy (in the presence or absence of hypertension) slows the progression of deterioration in renal function and may even arrest its progression if detected at the micro‐proteinuric stage.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here